A Phase 4 interventional study of Yangzheng Compound Mixture and Conventional Treatment in Carcinoma and Sleep Disorder, sponsored by ShuGuang Hospital. Active, not recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-31.
Sponsored by ShuGuang Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Carcinoma with a site in China — 37 open to participants now, 49 under way, 12 of them phase 3. Carcinoma · China.
Among the 101 studies in Carcinoma with a site in China, this one is the 2nd largest by enrollment of the 82 interventional ones that give a count, is one of 10 that started in 2021, is one of 4 in phase 4, reaches primary completion later than 3 of the 48 other live ones, and was the 50th registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →37 of the 101 studies in Carcinoma with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 18–80
AstraZeneca · Sites in China, United States, Australia and 13 more countries
Ages 18+
Pfizer · Sites in China, United States, Australia and 11 more countries
Ages 18+
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–80
Peking University People's Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 36 · Phase 3 22 · Phase 4 4
First in 2006; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,127 is above the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 72 across the 82 interventional studies, 145 across the 19 observational. Of the 29 that completed or were terminated, 13 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 101 have an industry lead sponsor. The 10 most frequent:
ShuGuang Hospital is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
ShuGuang Hospital has 1 study filed under Carcinoma — fewer than ten, so there is no comparison to draw.
9 of the studies in Carcinoma with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT07453706Chinese University of Hong KongThe Application of Sentire Surgical System Plus Patient Side Single Arm in Robotic Colorectal Surgery | 2027-03 |
| NCT06676527Jinling Hospital, ChinaVorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma | 2027-03-01 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
| NCT07400263Peking University People's HospitalEvaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors | 2027-06-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 101 studies in Carcinoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a nationwide, multicenter, randomized, prospective, real-world study. The purpose of this study is to evaluate the effect and safety of Yangzheng Compound Mixture in the treatment of sleep disorder in cancer patients with Qi-Yin deficiency syndrome during chemotherapy.
Sleep disturbance is one of the most common symptoms in cancer patients, the morbidity is about 60%. Drugs commonly used to treat sleep disorders include benzodiazepines, hypnotic antidepressants and melatonin receptors agonists. The short-term efficacy of these drugs has been proven in many clinical trials, but long-term medications bear the risk of adverse reactions and addiction.
Yangzheng Compound Mixture is an extract of several traditional Chinese medicines, used as a basic prescription for cancer therapy, especially for patients who received chemotherapy with Qi-Yin deficiency syndrome, which often lead to sleep disturbance, fatigue and anorexia. According to some clinical and basic studies, Yangzheng Compound Mixture also has antitumor and immunomodulatory effects.
In this study, about 10 research centers will participate. We planned to enroll 1526 cancer patients (1144 cases in the observation group and 382 cases in the control group) with Qi-Yin deficiency Syndrome and sleep disorders during the period of receiving chemotherapy or combination of chemotherapy. The dynamic random method was adopted in this study, participants will be randomly divided into the experimental group (Yangzheng Compound Mixture plus conventional treatment) and control group (conventional treatment only), all of them will be interviewed once every 3 weeks until the end of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Yangzheng Compound Mixture: 10mL, 2 doses each time, 3 times a day, three weeks for a course of treatment. Investigators recommended that the participants of experimental group should use Yangzheng Compound Mixture for 2 courses at least. Conventional treatment: Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy. The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine.
Drug: Yangzheng Compound Mixture · Other: Conventional Treatment
Antitumor therapies: chemotherapy or combined chemotherapy. Sleep disorders: includes but is not limited to pharmacotherapy and exercise therapy. The examination, diagnosis and treatment of other concomitant diseases and tumor complications are based on clinical routine. We will collect information about all the combined medicine.
Other: Conventional Treatment
At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance. Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions.
Also known as: Z10970042(NMPA Approval Number)
Including treatment of sleep disorders and tumor which shall follow the clinical guidelines.
Best effective rate for sleep disorder treatment
Proportion of participants with a minimum PSQI score \< 8 during the treatment period.
Time frame: Measurement was taken at week 6.
Effective rate for sleep disorder treatment
Proportion of participants with PSQI score \< 8 after the end of the different treatment courses.
Time frame: Measurement was taken at week 6.
Improvement rate for sleep disorder treatment
Proportion of participates whose PSQI score decreased during treatment compared with the baseline.
Time frame: Measurement was taken at week 6.
Change of PSQI score compared with baseline
The PSQI score difference between the end of different treatment courses and baseline.
Time frame: Baseline and week 6.
Score of Pittsburgh Sleep Quality Index (PSQI), Sleep duration, Sleep efficiency, Subjective sleep quality, Sleep latency.
1. The outcomes were evaluated using the PSQI scale. 2. Sleep duration: response to question 4; 3. Sleep efficiency= (hours slept/ hours in bed) \* 100%; Hours slept: response to question 4; Hours in bed: calculated from responses to questions 1 and 3; 4. Subjective sleep quality: response to question 9; 5. Sleep latency: response to question 2.
Time frame: Measurement was taken at week 6.
Incidence and severity of AE or SAE
AE: Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAE: A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.
Time frame: Start of treatment until 30 days after the last day of the sleep disorder treatment
Incidence and severity of ADR or SADR
All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. A SADR is a serious ADR according to the above criteria of SAE.
Time frame: Start of treatment until 30 days after the last day of the sleep disorder treatment
Use frequency of hypnotic agents
Response to question 6 of the PSQI scale.
Time frame: Up to 18 weeks since the start of treatment
Appetite
Appetite was evaluated by using the Cancer Appetite and Symptom Questionnaire(CASQ).
Time frame: Up to 18 weeks since the start of treatment
Fatigue
Fatigue was evaluated by using the Brief Fatigue Inventory(BFI).
Time frame: Up to 18 weeks since the start of treatment
Quality of life (QOL)
Quality of Life (QOL) was measured by using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30).
Time frame: Up to 18 weeks since the start of treatment
Traditional Chinese Medical symptoms scale
Traditional Chinese Medical (TCM) symptoms were measured from these six aspects: weakness, shortness of breath, palpitations, deficiency-heat and vexation, dry mouth, sweat. The minimum score is 0 and the maximum value is 18. Higher scores of TCM scale means a worse outcome.
Time frame: Up to 18 weeks since the start of treatment
Proportion of leukocyte-increasing drugs used
Proportion of participates used leukocyte-increasing medication during the treatment period
Time frame: Up to 18 weeks since the start of treatment
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2021 to primary completion in Sep 2023, 29 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ShuGuang Hospital